BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8522468)

  • 1. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
    Teng R; Harris SC; Nix DE; Schentag JJ; Foulds G; Liston TE
    J Antimicrob Chemother; 1995 Aug; 36(2):385-94. PubMed ID: 8522468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.
    Teng R; Liston TE; Harris SC
    J Antimicrob Chemother; 1996 May; 37(5):955-63. PubMed ID: 8737145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.
    Vincent J; Venitz J; Teng R; Baris BA; Willavize SA; Polzer RJ; Friedman HL
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():75-80. PubMed ID: 9222074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.
    Allen A; Bygate E; Vousden M; Oliver S; Johnson M; Ward C; Cheon A; Choo YS; Kim I
    Antimicrob Agents Chemother; 2001 Feb; 45(2):540-5. PubMed ID: 11158752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
    Vincent J; Teng R; Dalvie DK; Friedman HL
    Am J Surg; 1998 Dec; 176(6A Suppl):8S-13S. PubMed ID: 9935250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys.
    Teng R; Girard D; Gootz TD; Foulds G; Liston TE
    Antimicrob Agents Chemother; 1996 Mar; 40(3):561-6. PubMed ID: 8851571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.
    Vincent J; Dogolo L; Baris BA; Willavize SA; Teng R
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):427-30. PubMed ID: 9758287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.
    Melnik G; Schwesinger WH; Teng R; Dogolo LC; Vincent J
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):424-6. PubMed ID: 9758286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers.
    Allen A; Bygate E; Oliver S; Johnson M; Ward C; Cheon AJ; Choo YS; Kim IC
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1604-8. PubMed ID: 10817716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral bioavailability of trovafloxacin with and without food in healthy volunteers.
    Teng R; Dogolo LC; Willavize SA; Friedman HL; Vincent J
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():87-92. PubMed ID: 9222076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin.
    Williams DJ; Hopkins S
    Am J Surg; 1998 Dec; 176(6A Suppl):74S-79S. PubMed ID: 9935261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects.
    Vincent J; Hunt T; Teng R; Robarge L; Willavize SA; Friedman HL
    Am J Surg; 1998 Dec; 176(6A Suppl):32S-38S. PubMed ID: 9935255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men.
    Dickens GR; Wermeling D; Vincent J
    J Clin Pharmacol; 1997 Mar; 37(3):248-52. PubMed ID: 9089427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chemistry and biological profile of trovafloxacin.
    Brighty KE; Gootz TD
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():1-14. PubMed ID: 9222064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of trovafloxacin: its clinical significance].
    Clara LO; Biglia MA
    Medicina (B Aires); 1999; 59 Suppl 1():17-22. PubMed ID: 10436550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
    Wise R; Mortiboy D; Child J; Andrews JM
    Antimicrob Agents Chemother; 1996 Jan; 40(1):47-9. PubMed ID: 8787877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trovafloxacin: a new fluoroquinolone.
    Alghasham AA; Nahata MC
    Ann Pharmacother; 1999 Jan; 33(1):48-60. PubMed ID: 9972385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.
    Bradley JS; Kearns GL; Reed MD; Capparelli EV; Vincent J
    Antimicrob Agents Chemother; 2000 May; 44(5):1195-9. PubMed ID: 10770751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excretion and metabolism of trovafloxacin in humans.
    Dalvie DK; Khosla N; Vincent J
    Drug Metab Dispos; 1997 Apr; 25(4):423-7. PubMed ID: 9107540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of trovafloxacin into gynecologic tissues.
    Martens MG; Maccato M; Van Hook C; Vincent J
    Am J Surg; 1998 Dec; 176(6A Suppl):18S-22S. PubMed ID: 9935252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.